Ethena's ENA token surged from $0.014 to about $0.28 following the protocol's expansion of its yield strategy to include tokenized U.S. stocks as collateral and hedging via Binance stock perpetual contracts. The protocol is ending USDe growth incentives by September's end, which had already declined by 85% since 2024 after distributing over $750 million in rewards. Additionally, Ethena is accelerating investor token unlocks to October 5, 2026, ending the original schedule 17 months early. These moves mark a strategic shift from crypto basis trading toward tokenized stock markets, with significant changes to token issuance and supply dynamics.
Ethena's recent strategic changes in token incentives provide context for cryptocurrency market activity. For readers following crypto assets, here is Pluang's market snapshot as of Sep 28, 2026 20:22 WIB: out of 50 major cryptocurrencies, 11 rose and 38 fell. Notable moves include SXP down 46.27% at Rp37, ONE up 23.84% at Rp47 with a typical hold time of 152 days and a 70% buy order activity, and GRT up 15.16% at Rp577 with a typical hold time of 98 days and 87% sell order activity.
Vertex Pharmaceuticals reported a 12% revenue increase to $3.33 billion in Q2, driven by its dominant cystic fibrosis treatments. UBS raised its price target from $585 to $615, reflecting confidence in Vertex's strong financials and growth potential....
Accenture's stock surged 37.6% recently, driven by rising demand for AI services and new AI-focused offerings. The company outpaced industry growth and secured 100 new clients for advanced AI projects in one quarter. An analyst raised the price targe...
SpaceX, trading near $148 per share with a market cap of about $1.95 trillion, is preparing for Starship's first orbital mission and the deployment of its first operational Starlink V3 satellites. This milestone is key for expanding Starlink's global...
Argus Research initiated coverage on 10x Genomics with a Buy rating and a $110 price target, suggesting a 28% upside from its current price of around $85. The stock shows strong momentum, trading well above its 50-day and 200-day moving averages. How...
Morgan Stanley reaffirmed an "Overweight" rating on Cullen/Frost Bankers, Inc., raising its price target to $201, signaling confidence in the bank's prospects. Major institutional investors like State Street Corp and BlackRock have increased or initi...
